Cargando…

Changes in Sexual Function in Benign Prostatic Hyperplasia Patients Taking Dutasteride: 1-Year Follow-Up Results

PURPOSE: Sexual adverse events (AEs), a major cause for discontinuing 5α-reductase inhibitor (5ARI) therapy for benign prostatic hyperplasia (BPH), are known to occur most frequently early in therapy and appear to decline over time. The aim of this study was to investigate the changes in sexual func...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Byung Hoon, Kim, Sae Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198238/ https://www.ncbi.nlm.nih.gov/pubmed/22025960 http://dx.doi.org/10.4111/kju.2011.52.9.632

Ejemplares similares

Economic Evaluation for Benign Prostatic Hyperplasia in Iran: Surgical Treatment or Dutasteride
por: Khedmati, Jamaleddin, et al.
Publicado: (2021)

Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia
por: Thomson, Andrew
Publicado: (2005)

Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
por: Kosilov, Kirill V., et al.
Publicado: (2020)

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
por: Kuiper, Josephina G., et al.
Publicado: (2016)

The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis
por: Li, Yao, et al.
Publicado: (2022)

Update on the use of dutasteride in the management of benign prostatic hypertrophy
por: Miller, Joe, et al.
Publicado: (2007)

Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability
por: Barkin, Jack
Publicado: (2011)

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin
por: Djavan, Bob, et al.
Publicado: (2011)

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia
por: Zaitsu, Masayoshi, et al.
Publicado: (2013)

The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model
por: Da Silva, Marcello H A, et al.
Publicado: (2018)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
por: Gotoh, Daisuke, et al.
Publicado: (2022)

Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study
por: Laanani, Moussa, et al.
Publicado: (2023)

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
por: Toren, Paul, et al.
Publicado: (2013)

Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
por: Tsai, Tsen‐Fang, et al.
Publicado: (2018)

A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model
por: Udeh, Emeka I., et al.
Publicado: (2016)

Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials
por: Zhou, Zhongbao, et al.
Publicado: (2020)

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer
por: Seok, Jaekwon, et al.
Publicado: (2023)

Long-Term Follow-Up Results of Photoselective Vaporization of the Prostate with the 120 W Greenlight HPS Laser for Treatment of Benign Prostatic Hyperplasia
por: Kang, Se-Hee, et al.
Publicado: (2011)

Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study
por: Hagiwara, Kazuhisa, et al.
Publicado: (2016)

Preparation, Characterization and Stability Study of Dutasteride Loaded Nanoemulsion for Treatment of Benign Prostatic Hypertrophy
por: Ali, Mohammad Sajid, et al.
Publicado: (2014)

Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
por: Eisen, Christoph, et al.
Publicado: (2020)

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States
por: DerSarkissian, Maral, et al.
Publicado: (2016)

Benign Prostatic Hyperplasia
Publicado: (2015)

Outcomes of Top-Down Holmium Laser Enucleation of Prostate for Recurrent/Residual Benign Prostatic Hyperplasia: One-Year Follow-Up
por: Zakaria, Ahmed S., et al.
Publicado: (2022)

AB016. Which laser works best for benign prostatic hyperplasia?
por: Kim, Sae Woong
Publicado: (2015)

Effectiveness and Safety of Photoselective Vaporization of the Prostate with the 120 W HPS Greenlight Laser in Benign Prostatic Hyperplasia Patients Taking Oral Anticoagulants
por: Sohn, Jun Ho, et al.
Publicado: (2011)

It's Time to Take Advantage of Robotic Assisted Simple Prostatectomy in Large Benign Prostatic Hyperplasia
por: Kim, Myong, et al.
Publicado: (2019)

Current Laser Treatments for Benign Prostatic Hyperplasia
por: Son, Hwancheol, et al.
Publicado: (2010)

Sexual outcome of patients undergoing thulium laser enucleation of the prostate for benign prostatic hyperplasia
por: Carmignani, Luca, et al.
Publicado: (2015)

Prostatic Artery Embolization as a Treatment Option for Symptomatic Benign Prostatic Hyperplasia: Results from the Prospective Follow-Up Study in Lithuania
por: Jankauskas, Tautvydas, et al.
Publicado: (2023)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

The Effect of Intraprostatic Chronic Inflammation on Benign Prostatic Hyperplasia Treatment
por: Kwon, Young Kee, et al.
Publicado: (2010)

Preservation of Sexual Function 5 Years After Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia
por: McVary, Kevin T., et al.
Publicado: (2021)

The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia
por: Gandhi, Jason, et al.
Publicado: (2017)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Characteristics of prostate biopsy in patients under the dutasteride treatment
por: Obinata, Daisuke, et al.
Publicado: (2022)

Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting
por: Geitona, Maria, et al.
Publicado: (2014)

A 52‐week multicenter randomized controlled study of the efficacy and safety of add‐on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study)
por: Yamanishi, Tomonori, et al.
Publicado: (2018)

Metabolic syndrome and benign prostatic hyperplasia: An update
por: Ngai, Ho-Yin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_24qd8n0l6d2511ed5cp7jlrod6